Skip to content

US · CTXR · BIOTECHNOLOGY

Citius Pharmaceuticals, Inc. (CTXR) intrinsic value and stock valuation

$0.51as of 2026-11-21 · Mkt cap 7.62M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Citius Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values CTXR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CTXR’s statements →

Citius Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cranford, NJ 07016 citiuspharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-37.43M
20112025
Free cash flow
-$-26.55M
20112025
Total equity
$77.5M+18.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-38.53M-$-42M-$-36.73M-$-33.32M-$-23.53M
Net income-$-37.43M-$-39.14M-$-32.54M-$-33.64M-$-23.13M
EPSd-$-3.38M-$-3.38M-$-3.22M-$-3.45M-$-3.19M
Operating cash flow-$-26.55M-$-28.2M-$-29.06M-$-28.36M-$-24.25M
Capital expenditure$0.00$0.00$0.00$0.00-$-40.01M
Free cash flow-$-26.55M-$-28.2M-$-29.06M-$-28.36M-$-64.26M
Total assets$130.9M$116.7M$103.6M$114M$142.4M
Total debt$1.81M$260K$480K$680K$860K
Net debt-$-2.44M-$-2.99M-$-26M-$-41.03M-$-69.22M
Total equity$77.5M$74.1M$91.4M$103.4M$132.8M
Cash and short-term investments$4.25M$3.25M$26.5M$41.7M$70.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$210K$210K$190K$180K$160K
Gross profit-$-210K-$-210K-$-190K-$-180K-$-160K
Research and development expenses$9.16M$11.9M$14.8M$17.7M$12.2M
Selling, general and administrative expenses$18.5M$18.3M$21.9M$15.7M$11.3M
Other expenses$10.6M$11.8M$0.00$0.00$0.00
Operating expenses$38.3M$42M$36.7M$33.3M$23.5M
Cost and expenses$38.5M$42M$36.7M$33.3M$23.5M
Interest income$110K$760K$1.18M$250K$260K
Interest expense$270K$0.00$0.00$250K$10K
Depreciation and amortization$210K$210K$190K$180K$160K
Ebitda-$-38.2M-$-38.64M-$-31.77M-$-32.88M-$-22.88M
Operating income-$-38.53M-$-42M-$-36.73M-$-33.32M-$-23.53M
Total other income/expenses, net-$-160K$3.15M$4.77M$250K$480K
Income before tax-$-38.68M-$-38.85M-$-31.97M-$-33.06M-$-23.05M
Income tax expense$1.06M$580K$580K$580K$0.00
Net income-$-37.43M-$-39.14M-$-32.54M-$-33.64M-$-23.13M
Weighted average shares outstanding$11.1M$11.6M$9.74M$9.74M$7.24M
Weighted average diluted shares outstanding$11.1M$11.6M$10.1M$9.74M$7.24M
Balance sheet
20252024202320222021
Cash and short-term investments$4.25M$3.25M$26.5M$41.7M$70.1M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$22.3M$8.27M$0.00$0.00$0.00
Total current assets$27.9M$14.2M$34.4M$44.6M$72.8M
Property, plant and equipment, net$820K$250K$460K$650K$830K
Goodwill and intangible assets$102.2M$102.2M$68.8M$68.8M$68.8M
Long-term investments$0.00$0.00$44.9M$0.00$29.2M
Total non-current assets$103M$102.4M$69.2M$69.4M$69.6M
Total assets$130.9M$116.7M$103.6M$114M$142.4M
Accounts payable$13.7M$4.93M$2.93M$1.17M$1.28M
Short-term debt$1.09M$480K$440K$390K$350K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$44.9M$35.8M$5.78M$4.53M$3.98M
Long-term debt$720K$20K$260K$480K$680K
Deferred revenue, non-current$0.00$0.00-$-10K-$-10K-$0.00
Total non-current liabilities$8.5M$6.74M$6.4M$6.04M$5.66M
Capital lease obligations$810K$260K$480K$680K$860K
Total liabilities$53.4M$42.6M$12.2M$10.6M$9.65M
Common stock$20K$10K$160K$150K$150K
Retained earnings-$-238.8M-$-201.37M-$-162.23M-$-129.69M-$-96.05M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$77.5M$74.1M$91.4M$103.4M$132.8M
Total investments$0.00$0.00$44.9M$0.00$29.2M
Total debt$1.81M$260K$480K$680K$860K
Net debt-$-2.44M-$-2.99M-$-26M-$-41.03M-$-69.22M
Cash flow statement
20252024202320222021
Net income-$-39.74M-$-39.43M-$-32.54M-$-33.64M-$-23.05M
Depreciation and amortization$210K$210K$190K$180K$160K
Stock-based compensation$10.8M$11.8M$6.62M$3.91M$1.45M
Change in working capital$1.05M-$-1.69M-$-4.01M$240K-$-2.72M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory-$-12.65M-$-2.13M$0.00$0.00$0.00
Accounts payable$8.77M$2M$1.76M-$-110K-$-580K
Net cash provided by operating activities-$-26.55M-$-28.2M-$-29.06M-$-28.36M-$-24.25M
Investments in property, plant and equipment-$-5.75M$0.00$0.00$0.00-$-40.01M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-5.75M-$-5M$0.00$0.00-$-40.01M
Common stock issued$32.3M$13.8M$13.8M$0.00$89.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$33.3M$9.97M$13.8M$0.00$120.5M
Net change in cash$1M-$-23.23M-$-15.23M-$-28.36M$56.2M
Cash at end of period$4.25M$3.25M$26.5M$41.7M$70.1M
Operating cash flow-$-26.55M-$-28.2M-$-29.06M-$-28.36M-$-24.25M
Capital expenditure$0.00$0.00$0.00$0.00-$-40.01M
Free cash flow-$-26.55M-$-28.2M-$-29.06M-$-28.36M-$-64.26M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Citius Pharmaceuticals, Inc.

        Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

        CEO
        Leonard L. Mazur
        Employees
        23
        Beta
        0.98

        Explore

        Frequently asked questions

        What is the intrinsic value of Citius Pharmaceuticals, Inc. (CTXR)?

        InvestorsCraft does not currently publish an intrinsic value for CTXR. How the IC value is calculated.

        Is CTXR undervalued?

        InvestorsCraft does not publish an undervaluation signal for CTXR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.